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Abstract
A series of radiolabeled cyclic arginine–glycine–
aspartic acid (RGD) peptide ligands for cell adhesion
molecule integrin AvB3–targeted tumor angiogenesis
targeting are being developed in our laboratory. In this
study, this effort continues by applying a positron
emitter 64Cu-labeled PEGylated dimeric RGD peptide
radiotracer 64Cu-DOTA-PEG-E[c(RGDyK)]2 for lung can-
cer imaging. The PEGylated RGD peptide indicated
integrin AvB3 avidity, but the PEGylation reduced the
receptor binding affinity of this ligand compared to the
unmodified RGD dimer. The radiotracer revealed rapid
blood clearance and predominant renal clearance
route. The minimum nonspecific activity accumulation
in normal lung tissue and heart rendered high-quality
orthotopic lung cancer tumor images, enabling clear
demarcation of both the primary tumor at the upper
lobe of the left lung, as well as metastases in the me-
diastinum, contralateral lung, and diaphragm. As a com-
parison, fluorodeoxyglucose (FDG) scans on the same
mice were only able to identify the primary tumor,
with the metastatic lesions masked by intense cardiac
uptake and high lung background. 64Cu-DOTA-PEG-
E[c(RGDyK)]2 is an excellent positron emission tomo-
graphy (PET) tracer for integrin-positive tumor imaging.
Further studies to improve the receptor binding affinity
of the tracer and subsequently to increase the magni-
tude of tumor uptake without comprising the favorable
in vivo kinetics are currently in progress.
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Introduction
Lung cancer is the leading cause of cancer death for both
men and women, killing more people than breast, prostate,
colon, and pancreas cancers combined [1]. The major
histologic types of lung cancer are squamous cell carci-
noma, adenocarcinoma, large cell carcinoma (referred to as
non small cell lung cancer, or NSCLC) and small cell lung
carcinoma (SCLC). Early detection and treatment may lead
to improved survival for some types of lung cancer [2]. Even
patients with the earliest surgical stage (T1N0) have dissemi-
nated disease between 15% and 30% of the time [3]. Chemo-
therapy, surgery, and radiation therapy have been shown to
control symptoms and improve quality of life; there remains no
standard optimal therapy regimen for NSCLC [4]. The mecha-
nisms of resistance to drug and radiation therapy are poorly
understood [5]. Despite significant progress, the molecular
events underlying the development of lung cancer are largely
unknown. No drug has been found useful in the prevention of
lung cancer [6]. Although there are proven means of early
diagnosis available for lung cancer, whether these techniques
are effective in terms of improving patient survival or outcome
remains unknown [7].
Lung cancer diagnosis based on histopathology requires
fine-needle biopsy, bronchoscopy, or open-lung biopsy to
differentiate benign from malignant lesions, before and
often after surgical resection or radiation therapy of the primary
tumor lesions. Bronchoscopy, including bronchial washings
and brushing, has a sensitivity of 65% for malignancy, and
transbronchial biopsy increases the sensitivity to 80% for
lesions that are accessible. Pneumothorax and associated
morbidity can occur following these invasive procedures. Con-
ventional anatomic imaging techniques such as chest X-ray,
computed tomography (CT) scans, bone scans, or magnetic
resonance imaging (MRI) can neither accurately stage the
disease when metastases occurs without anatomic change,
nor differentiate between malignant and nonmalignant tumors.
Fluorodeoxyglucose positron emission tomography (FDG-
PET) imaging, which visualizes glucose utilization by lung
cancer cells, is increasingly used for the management of
patients with lung cancer, especially those with NSCLC.
FDG-PET quantifies a specific cellular process, namely, phos-
phorylation of 2-deoxyglucose by hexokinase. The technique
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provides highly sensitive and specific data for the diagnosis,
staging, and restaging of NSCLC, without the need for a
biopsy, and is now well accepted by most physicians as an
effective complement to existing imaging modalities [8–10].
FDG-PET may also evolve as a predictor of response after
local or systemic treatment [11].
Although assessment of tissue metabolism using the
tracer FDG provides useful imaging of lung neoplasms, it
is relatively nonspecific and is usually less useful for imaging
tumors that have very low growth rates, or as a guide for
delivery of specific molecular therapy. The development of
tracers that target specific molecular or genetic abnormali-
ties, which are the basis of lung cancer, is therefore essential
for the development and utility of clinically relevant PET
procedures that can be use to assess the efficacy of thera-
peutic drugs designed to treat those abnormalities. The
goals are: to allow early detection and characterization of
the disease, to provide more timely and direct assessments
of treatment effects, and to obtain more fundamental under-
standing of the disease process. The rapidly expanding
knowledge of the molecular pathogenesis of lung cancer
indicates that respiratory epithelial cells require many ge-
netic alterations to become invasive, leading to metastatic
cancer. In addition, most solid tumors are angiogenesis-
dependent [12]. Antiangiogenic therapy has been shown to
prevent tumor growth and even to cause tumor regression in
various tumor models including lung cancer [13]. NSCLC
growth, angiogenesis, invasion, and metastases to specific
organs are dependent on an orchestrated series of events
that include: cellular transformation; establishment of a
proangiogenic environment; tumor cell proliferation, inva-
sion, and entry into the circulation; and tumor cell trafficking
and metastatic tumor growth in specific organs [14]. Cell
adhesion receptors of the integrin family, which are respon-
sible for a wide range of cell–extracellular matrix (ECM) and
cell–cell interactions, have been well studied in many tumor
types including brain, breast, skin, and ovarian tumors.
However, little is known regarding the function of integrins
in lung cancer growth and metastasis [15].
Due to its high expression on tumor vasculature and
tumor cells compared to resting endothelial cells and normal
tissues, avb3 integrin is an excellent target for integrin-
targeted interventions [16,17]. It has been shown that
avb3 integrin antagonists, such as monoclonal antibodies,
arginine–glycine–aspartic acid (RGD) peptides, and small
molecules, block angiogenesis and tumor growth by selec-
tively promoting apoptosis of vascular endothelial cells
[16–18]. The development of noninvasive methods to visu-
alize and quantify av integrin expression in vivo appears to be
crucial for the success of antiangiogenic therapy based on
integrin antagonism [17,19]. A number of molecular probes
have been developed for MRI [20,21], PET [22–30], single-
photon computed tomography (SPECT) [31–35], and ultra-
sound [36] imaging applications.
64Cu-labeled RGD peptides are of particular interest
because 64Cu [t1/2 = 12.8 h; 40% b
 (656 keV); 19% b+
(600 keV); 38% EC] is an attractive radionuclide for both
PET imaging and targeted radiotherapy of cancer [37].
We first coupled monomeric RGD peptide c(RGDyK) with
the macrocyclic chelator, 1,4,7,10-tetraazacyclododecane-
N,NV,NW,Nj-tetraacetic acid (DOTA), and labeled the RGD-
DOTA conjugate with 64Cu for tumor targeting. The
radiotracer showed intermediate tumor uptake but also high
retention in liver and kidney [23]. Introduction of a bifunctional
poly(ethylene glycol) (PEG; MW = 3,400) moiety between
DOTA and RGD led to significantly improved in vivo kinetics
of the resulting radiotracer 64Cu-DOTA-PEG-RGD com-
pared to that of 64Cu-DOTA-RGD [25]. We also observed
that a dimeric RGD peptide E[c(RGDyK]2 with higher integrin
binding affinity, when conjugated with DOTA and labeled
with 64Cu, yielded almost twice as much uptake in tumors, as
well as significantly increased renal activity accumulation
compared to the monomeric analogue [27]. In this study, we
sought to extend this effort by examining integrin expression
in lung cancer using noninvasive PET imaging and a novel
radiotracer—64Cu-labeled PEGylated dimeric RGD peptide
64Cu-DOTA-PEG-E[c(RGDyK)]2 (Figure 1).
Materials and Methods
Materials and Analyses
DOTAwas purchased fromMacrocyclics, Inc. (Dallas, TX).
N-hydroxysulfonosuccinimide (SNHS), 1-ethyl-3-[3-(dime-
thylamino)propyl]carbodiimide (EDC), and Chelex 100
(50–100 mesh) were obtained from Aldrich (St. Louis,
MO). Heterofunctional PEG (MW 3400), t-Boc-NH-PEG-
CO2NHS, was obtained from Nektar, Inc. (San Carlos, CA).
Cyclic RGD peptide c(RGDyK) was synthesized through
solution cyclization of the fully protected linear pentapep-
tide, H-Gly-Asp(OtBu)-D-Tyr(OtBu)-Lys(Boc)-Arg(Pbf)-OH,
followed by TFA deprotection [22–24]. Dimeric RGD peptide
E[c(RGDyK)]2 was prepared by coupling Boc-Glu-OH
with two equivalents of monomeric RGD peptide c(RGDyK)
followed by TFA cleavage [26,27]. Radio-thin layer chroma-
tography (TLC) was performed using MKC18F plates (What-
man, Clifton, NJ), a Bioscan system 200, and Winscan
(Washington, DC) software, version 2.2. Reversed-phase
extraction C-18 SepPak cartridges were obtained from
Waters (Milford, MA). 64Cu was produced on a CS-15
biomedical cyclotron at THE Washington University School
of Medicine by the 64Ni(p,n)64Cu nuclear reaction [37].
Chromalux HB microplates were obtained from Dynex Tech-
nologies (Chantilly, VA). [125I]echistatin labeled by the lacto-
peroxidase method to a specific activity of 2000 Ci/mmol was
from Amersham Biosciences (Piscataway, NJ). Echistatin
was purchased from Sigma (St. Louis, MO).
Semipreparative reversed-phase high-performance liquid
chromatography (HPLC) was accomplished on a Waters
515 chromatography system with a 486 tunable absorbance
detector. Version 7.2.1 Labtech Notebook/XE software
(Andover, MA) was used to record chromatograms. Puri-
fication was performed on a Vydac protein and peptide
column 218TP510 (5 mm, 250  10 mm). The flow was
5 ml/min, with the mobile phase starting from 95% solvent
A (0.1% TFA in water) and 5% solvent B (0.1% TFA in
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acetonitrile) (0–2 min) to 35% solvent A and 65% solvent B
at 32 minutes. The analytical HPLC method was performed
with the same gradient system, but with a Vydac 218TP54
column (5 mm, 250  4.6 mm) and flow of 1 ml/min. UV
absorbance was monitored at 218 nm.
Chemistry and Radiochemistry
t-Boc-NH-PEG-E[c(RGDyK)]2 conjugate t-Boc–protected
PEG succinimidyl ester (t-Boc-NH-PEG-CO2NHS, MW =
3400), 30 mg (ca. 8.8 mmol), dissolved in acetonitrile (2 ml);
E[c(RGDyK)]2, 16 mg (ca. 11.8 mmol), dissolved in water
(2 ml); and 0.2 M Na2B4O7 buffer (pH = 8.3), 2 ml, were
mixed together and incubated overnight at 4jC. The reaction
was quenched by adding 5% HOAc (0.5 ml) and the entire
mixture was then subjected to several semipreparative
HPLC purifications. Removal of the mobile phase gave the
product as a lyophilized solid. Yield: 30 mg (ca. 70% based
on PEG).
NH2-PEG-E[c(RGDyK)]2 Twenty milligrams of t-Boc-NH-
PEG-E[c(RGDyK)]2 conjugate was dissolved in 2 ml of
95% TFA and allowed to stand at room temperature for 2 h.
Most of the TFA was then removed by rotary evaporator
(equipped with a CO2/acetone cold finger, oil pump, and acid
trap). The residue was triturated with ice-cold ether (10 ml)
to precipitate the crude peptide. Semipreparative HPLC
purification followed by lyophilization gave the unprotected
RGD–PEG conjugate. Yield: 15 mg (ca. 75%).
DOTA-PEG-E[c(RGDyK)]2 DOTA was activated in situ by
EDC with a DOTA:EDC:SNHS molar ratio of 10:5:4 [23].
NH2-PEG-E[c(RGDyK)]2 (10 mg, ca. 2.1 mmol) dissolved in
2 ml of water was cooled to 4jC and added to the DOTA-
OSSu reaction mixture (20 mmol; calculated based on SNHS)
and the pH was adjusted to 8.5 with 1 N NaOH. The reaction
was allowed to incubate overnight at 4jC. The DOTA-PEG-
E[c(RGDyK)]2 conjugate was purified by semipreparative
HPLC and characterized by analytical HPLC and matrix-
assisted laser desorption/ionization time-of-flight mass spec-
troscopy (MALDI-TOF MS). Yield: 6.5 mg (ca. 60%). The
peak containing the RGD conjugate was collected, lyophi-
lized, and dissolved in H2O at a concentration of 1 mg/ml for
use in radiolabeling reactions.
64Cu radiolabeling 64CuCl2 (5 mCi, decay-corrected)
was diluted with 400 ml of 0.1 N NaOAc (pH 5.5) and then
added to DOTA-PEG-E[c(RGDyK)]2 (25 mg). The reaction
mixture was incubated at 50jC for 50 minutes and then
terminated by adding 5 ml of 10 mM EDTA solution. Radio-
chemical yield was determined by radio-TLC usingWhatman
MKC18F TLC plates as the stationary phase and 70:30
MeOH:10% NaOAc as the eluent. 64Cu-DOTA-PEG-E
[c(RGDyK)]2 was purified on a C-18 SepPak cartridge, using
85% ethanol as the elution solvent. Radiochemical purity
(RCP) was determined by radio-TLC or radio-HPLC. The
ethanol was evaporated, and the activity was reconstituted in
phosphate-buffered saline and passed through a 0.22-mm
Millipore (Billerica, MA) filter into a sterile multidose vial for
use in animal experiments.
Receptor Binding Assay
Affinity of echistatin and RGD peptides for avb3 integrin on
the surface of NSCLC NCI-H1975 cells was determined by
competitive binding experiments using 125I-labeled echistatin
as a radioligand as described in the literature, with modifica-
tions [38]. In brief, NCI-H1975 cells were harvested, washed
Figure 1. Schematic structure of DOTA-PEG-E[c(RGDyK)]2. Heterobifunctional PEG (MW = 3400) links to DOTA carboxylate group through the N-terminus and to
the glutamate amino group of the dimeric RGD peptide through the C-terminus.
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twice with PBS, and resuspended (2  106 cells/ml) in
binding buffer (20 mM Tris, pH 7.4, 150 mM NaCl, 2 mM
CaCl2, 1 mM MgCl2, 1 mM MnCl2, and 0.1% BSA). Ninety-
six–well multiscreen DV plates (filter pore size: 0.65 mm;
Millipore) were incubated with [125I]echistatin (50,000 cpm/
well) in the presence of increasing concentrations of different
RGD peptide analogues (0–1000 nM). The total incubation
volume was adjusted to 200 ml. After the cells were incubated
for 3 hours at room temperature, the plate was filtered
through a multiscreen vacuum manifold and washed twice
with cold binding buffer. The hydrophilic PVDF filters were
collected and the radioactivity was determined using a
NaI(Tl) gamma counter (Packard, Meriden, CT). The best-
fit IC50 values for the NCI-H1975 cells were calculated by
fitting the data by nonlinear regression using GraphPad
Prism (GraphPad Software, Inc., San Diego, CA). Experi-
ments were carried out with triplicate samples.
In Vivo Model
The University of Southern California Institutional Animal
Care and Use Committee approved the animal study de-
scribed herein. All animals received humane care in compli-
ance with the ‘‘Guide for the Care and Use of Laboratory
Animals’’ published by the National Institutes of Health.
Six-week–old severe combined immunodeficient (SCID-
bg male mice; Harlan Sprague Dawley, Inc., Indianapolis, IN)
mice were housed in polycarbonate cages (five per cage) in
a room lit for 12 hours each day and maintained at 27jC for
2 days prior to injection. Teklad (4%) diet (Harlan Teklad,
Madison, WI) and tap water were provided ad libitum. In
preparation for injection, human female lung adenocar-
cinoma cells NCI-H1975 (American Type Culture Collection,
Manassas, VA) were cultured in RPMI 1640 supplemented
with 10% fetal bovine serum (GIBCO, Carlsbad, CA) until
90% confluent. Cells were trypsinized, washed, centrifuged,
and resuspended to a concentration of 2  106 cells/30 ml
in RPMI 1640 (cell passages 35 ± 3). Mice were anesthe-
sized by titrating isoflurane inhalant. A 1-cm axillary incision
allowed left lung visualization through intercostal muscles
and pleura. NCI-H1975 cell suspension was injected through
a 27-gauge needle into the left upper lobe at the fourth
intercostal space under direct visualization. The incision
was closed using 4.0 absorbable suture, and mice were
allowed to recover [39]. Mice were subjected to microPET
imaging and whole-body digital autoradiography (WBDA)
studies at 4 weeks after implantation.
Biodistribution
Male SCID-bg mice bearing subcutaneous NCI-H1975
tumors (n = 3 per time point) were injected with 64Cu-DOTA-
PEG-E[c(RGDyK)]2 (10 mCi activity in 150 ml of saline)
through the tail vein. The animals were euthanized at 0.5,
1, 2, 4, and 24 hours postinjection. The blocking experiment
was performed by coinjecting the radiotracer with a saturat-
ing dose of c(RGDyK) (10 mg/kg) and was sacrificed at
1 hour postinjection. Following euthanasia, blood, tumor,
and major organs and tissues were collected, wet-weighed,
and counted in a g-counter (Packard). Percent injected dose
per gram (% ID/g) was calculated by comparison with stan-
dards representing the injected dose per animal. Values are
quoted as mean ± standard deviation (SD). To compare the
in vivo kinetics of 64Cu-DOTA-PEG-E[c(RGDyK)]2 and
64Cu-
DOTA-E[c(RGDyK)]2, biodistribution studies of both tracers
were performed in female athymic nude mice at 30-minute,
1-hour, 2-hour, 4-hour, and 24-hour time points (10 mCi
activity for each animal; n = 4 per time point).
MicroPET Imaging and WBDA
PET imaging was performed on a microPET R4 rodent
model scanner (Concorde Microsystems, Inc., Knoxville, TN).
The scanner has a computer-controlled bed, and 10.8 cm
transaxial and 8 cm axial field of view (FOV). It has no
septa and operates exclusively in 3D list mode. All raw data
were first sorted into 3D sinograms followed by maximum a
posteriori (MAP) reconstruction based on a Bayesian formu-
lation, which combines accurate modeling of the coincidence
detection process with statistical priors on the PET images
[40]. At 4 weeks postinoculation, orthotopic tumor-bearing
mice were anesthetized by intraperitoneal injection of ket-
amine/xylazine solution, placed in a spread-supine position
on a cardboard slat, and injected with 200 mCi of [18F]FDG
into the tail vein at a volume of 150 ml. The mice were
scanned for 10 minutes starting from 30 minutes after FDG
injection. The same mice were intravenously injected with
300 mCi of 64Cu-DOTA-PEG-E[c(RGDyK)]2 and sacrificed at
1 hour postinjection by cervical dislocation under ketamine/
xylazine anesthesia and placed near the center of the FOV
of the microPET, where the highest image resolution and
sensitivity are available. The mice were scanned for 20 min-
utes followed by whole-body autoradiography, using a
Packard Cyclone Storage Phosphor Screen system (Down-
ers Grove, IL) and a Bright 5030/WD/MR cryomicrotome
(Hacker Instruments, Fairfield, NJ) [22]. Regions of interest
(ROI) for microPET imaging were drawn over subcutaneous,
orthotopic, andmetastatic tumors on decay-corrected whole-
body coronal images. The counts per pixel per minute ob-
tained from the ROIs were converted to counts per milliliter
per minute by using a system calibration factor obtained from
scanning a cylinder phantom in the microPET scanner. The
uptake index [ROI (mCi/ml)/injected dose (mCi)  100%]
of tissues and organs of interest was compared with the
percent injected dose per gram value obtained from direct
tissue sampling after the microPET imaging. Quantification
of autoradiographic images was validated by correlating the
ROIs in tissues [as detector light units (DUL)/mm2] with
direct gamma counter assays of the tissue samples removed
from the frozen block (n = 3). A linear relationship between
tissue percent injected dose per gram and autoradiography
image intensity was observed, and the conversion factor thus
obtained and used for autoradiography quantification [41].
Statistical Analysis
The data were expressed as mean ± SD. One-way
analysis of variance (ANOVA) was used for statistical
evaluation. Means were compared using Student’s t-test.
P values < .05 were considered significant.
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Results
Preparation of PEGylated Dimeric RGD Conjugate
and Radiolabeling
The synthetic scheme of DOTA-PEG-E[c(RGDyK)]2 is
shown in Figure 2. The PEGylated conjugate was obtained
by solution synthesis through an active ester protocol in 30%
overall yield calculated from t-Boc-NH-PEG-CO2NHS. Each
intermediate was characterized by analytical HPLC and
molecular weight measurement by MALDI-TOF MS. The
HPLC (under the conditions described in the Materials and
Methods section) retention times for E[c(RGDyK)]2, t-Boc-
NH-PEG-E[c(RGDyK)]2, NH2-PEG-E[c(RGDyK)]2, and
DOTA-PEG-E[c(RGDyK)]2 were 13.8, 23.7, 21.4, and
22.8 minutes, respectively. The mass spectrum of PEGylated
RGD dimer was characterized by broad peaks due to poly-
dispersiveness of PEG, with an average PEG size f3400.
The molecular weight of the final DOTA-PEG-E[c(RGDyK)]2
was around 5100, indicating a 1:1:1 molar ratio with respect
to DOTA, PEG, and E[c(RGDyK)]2. The
64Cu-DOTA-PEG-
E[c(RGDyK)]2 was prepared in high specific activity. Typi-
cally, 10 mg of peptide was able to bind 1 mCi of 64Cu with
> 95% radiochemical yield after 1 hour of incubation in
NaOAc buffer (pH = 5.5) as determined by radio-TLC.
SepPak separation provided the product with RCP higher
than 99%. The specific activity was thus calculated to be
around 500 Ci/mmol (decay-corrected).
In Vitro and In Vivo Evaluation
To characterize avb3 integrin binding properties of the
64Cu-labeled PEGylated dimeric RGD peptide, competitive
binding assay studies were performed. Maintenance of
binding affinity was shown by competitive binding measure-
ments between [125I]echistatin and the RGD peptide ligands
with cultured NCI-H1975 cells (Figure 3). The binding of
[125I]echistatin to NCI-H1975 cells was inhibited by various
concentrations of echistatin, c(RGDyK), E[c(RGDyK)]2, or
DOTA-PEG-E[c(RGDyK)]2, with IC50 values of 0.54, 44.8,
11.1, and 84.9 nM, respectively.
Comparison of biodistribution data of 64Cu-DOTA-PEG-
E[c(RGDyK)]2 and
64Cu-DOTA-E[c(RGDyK)]2 in the blood,
muscle, liver, and kidneys of female athymic nude mice is
shown in Figure 4. The PEGylated RGD peptide had similar
blood activity as 64Cu-DOTA-E[c(RGDyK)]2 at early time
points, but displayed a more rapid blood clearance than
64Cu-DOTA-E[c(RGDyK)]2 after 4 hours postinjection. The
PEGylated RGD dimmer indicated significantly lower activ-
ity accumulation in the muscle, liver, and kidneys at all
time points examined (P < .001). Overall, 64Cu-DOTA-
PEG-E[c(RGDyK)]2 was excreted with a faster rate than
64Cu-DOTA-E[c(RGDyK)]2.
In vivo biodistribution studies of 64Cu-DOTA-PEG-
E[c(RGDyK)]2 were performed in healthy male SCID-bg
mice implanted subcutaneously with human NSCLC
tumors grown from NCI-H1975 cells. Table 1 summarizes
results of the biodistribution pattern of 64Cu-DOTA-PEG-
E[c(RGDyK)]2 in tumor-bearing SCID mice at 0.5, 1, 2, 4,
and 24 hours. The PEGylated RGD peptide tracer showed
rapid blood clearance (0.57 ± 0.19% ID/g at 30 minutes
postinjection and only 0.05 ± 0.01% ID/g at 2 hours post-
injection). Highest tumor uptake was observed at 1 hour
postinjection (2.64 ± 0.14% ID/g) and some washout was
observed (1.15 ± 0.07% ID/g at 24 hours postinjection). Due
to the rapid clearance of the radiotracer, good tumor-to-blood
and tumor-to-muscle ratios were achieved after 1 hour
postinjection. It is also noteworthy to mention that this
PEGylated RGD peptide tracer produced a good tumor-to-
lung ratio because of low lung activity accumulation. The
Figure 2. Step-by-step synthesis of the PEGylated dimeric RGD peptide ligand, DOTA-PEG-E[c(RGDyK)]2.
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primary route of clearance of radiolabel from 64Cu-DOTA-
PEG-E[c(RGDyK)]2 was through the kidneys into the urine.
Only 0.94 ± 0.20% ID/g and 0.90 ± 0.35% ID/g were found in
the liver and intestines at 1 hour postinjection, respectively. It
is also important to note that there was minimal uptake of
64Cu in organs other than the kidneys, indicating that these
normal tissues and organs exhibit little avb3 integrin expres-
sion, which is consistent with previous reports [22–33]. To
demonstrate that the 64Cu-DOTA-PEG-E[c(RGDyK)]2 up-
take in NCI-H1975 tumor was specific and receptor-mediated,
biodistribution studies were performed by coinjection of
c(RGDyK) (10 mg/kg) with 64Cu-DOTA-PEG-E[c(RGDyK)]2.
An uptake value of 0.68 ± 0.10% ID/g was observed at 1 hour
postinjection, which was about four times lower than the
tumor uptake of 64Cu-DOTA-PEG-E[c(RGDyK)]2 when no
blocking agent was coinjected.
MicroPET and Autoradiography
We used microPET to semiquantitatively image the integ-
rin expression in the orthotopic lung cancer tumor and its
metastases. A 2D projection image of a mouse injected
2 hours previously with 64Cu-DOTA-PEG-E[c(RGDyK)]2
(15-minute static scan) is shown in Figure 5. The primary
tumor (left upper lobe at the fourth intercostal space) and its
metastasis to the contralateral lung were both well visual-
ized. By comparison, an FDG scan on the same mouse
identified the primary tumor but failed to visualize any
metastasis, probably due to significant nearby myocardial
uptake. A coronal section including the primary orthotopic
tumor and subcutaneous tumor on the right flank clearly
delineates the primary tumor and its metastases to the
contralateral lung, mediastinum, and diaphragm. Whole-
body autoradiography (100 mm resolution) agreed well with
the findings of microPET (Fig. 5). ROI analysis of the FDG-
PET images showed a primary tumor-to-muscle ratio of 4.8
and a primary tumor-to-lung ratio of 1.5. SUV. The RGD
peptide tracer had much higher tumor-to-background con-
trast than that of FDG, following the trend of subcutaneous
tumor > primary tumor > metastasis (contralateral lung).
Discussion
This study demonstrates that 64Cu-DOTA-PEG-E[c(RGDyK)]2
is an excellent positron-emitting radionuclide tracer for
visualization of NSCLC tumor and its metastases based on
integrin expression. The high tumor-to-lung contrast is due to
Figure 3. Competition of specific binding of [125I]echistatin with unlabeled
echistatin, c(RGDyK), E[c(RGDyK)]2, and DOTA-PEG-E[c(RGDyK)]2 on
integrin av3 expressed on the surface of human NSCLC NCI-H1975 cells.
All points represent triplicate measurements. PEGylation reduced the
receptor binding affinity of the resulting ligand from 11 to 85 nM.
Figure 4. Comparison of biodistribution data of 64Cu-DOTA-PEG-E[c(RGDyK)]2 (o) and
64Cu-DOTA-E[c(RGDyK)]2 (.) in female athymic nude mice. Error bars
denote SD (n = 4).
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the lack of integrin expression in normal tissues and organs,
and consequently minimal nonspecific cardiac and lung
activity accumulation with this radiotracer. The same tumor-
bearing mouse imaged with FDG showed low tumor contrast
and inability to delineate tumor metastases due to intense
cardiac uptake.
Most solid tumors are angiogenesis-dependent and,
therefore, various antiangiogenic treatment targetings at dif-
ferent molecular mechanisms are being explored [13,42,43].
With growing numbers of antiangiogenic drugs available
that target different pathways, it may become useful to select
therapeutic regimens based on the molecular characteristics
of tumors in individual patients as identified by selective
in vivo imaging agents. Overexpression of integrin avb3 on
both tumor cells and sprouting tumor vasculature, but not on
most normal tissues and resting endothelial cells, presents
an excellent target for antiangiogenic interventions [16].
Recent clinical trials and preclinical studies suggest that
avb3 expression correlates positively with tumor metastatic
potential and that anti-integin therapy using avb3 antagonists
is most effective with integrin-positive tumors [16,18]. Non-
invasive imaging of avb3 expression is thus of vital impor-
tance for patient selection and noninvasive monitoring of
anti-integrin treatment efficacy [17,19].
A series of cyclic RGD peptides has been labeled with 18F
(t1/2 = 109.7 minutes) for PET imaging of tumor integrin
expression [22,23,25,26,29,30]. The introduction of a fairly
bulky prosthetic 18F labeling group (4-[18F]fluorobenzoyl or
2-[18F]fluoropropionate) to the monomeric RGD peptide
results in unfavorable hepatobiliary excretion and rapid
tumor washout [22,23]. Inserting an amino sugar [29,30] or
PEG [25] moiety between the integrin binding RGD se-
quence and 18F label increases hydrophilicity and thus
improves tumor targeting efficacy and pharmacokinetics of
the resulting radiotracers. Recently, it has also been found
that an 18F-labeled dimeric RGD peptide with higher receptor
binding affinity than the corresponding monomeric counter-
part produces significantly increased tumor uptake and shifts
radiolabel clearance from the hepatobiliary route for the
monomer to a predominantly renal route for the dimer [26].
Despite the success of 18F-labeled RGD peptides for
imaging integrin expression in various preclinical tumor
models, it is important also to develop RGD peptides labeled
with a radiometal such as 64Cu (t1/2 = 12.7 hours) for PET
imaging because of the existence of imaging/therapy radio-
nuclide pairs of these metals (i.e., 64Cu/67Cu and 86Y/90Y).
Radiotracers labeled with the ‘‘imaging’’ isotope can be used
to determine dosimetry and to monitor tumor response for
the same ligand labeled with the corresponding therapeutic
isotope. With this purpose in mind, we initially conjugated
the macrocyclic chelator DOTA with the monomeric RGD
Table 1. Biodistribution of 64Cu-Labeled PEGylated Dimeric RGD Peptide (64Cu-DOTA-PEG-E[c(RGDyK)]2) in Male SCID-bg Mice Bearing Subcutaneous
NCI-H1975 NSCLC Tumors on the Right Flank.
0.5 hour 1 hour 2 hours 4 hours 24 hours 1-hour block
Blood 0.57 ± 0.19 0.17 ± 0.02 0.05 ± 0.01 0.04 ± 0.02 0.04 ± 0.01 0.16 ± 0.04
Muscle 0.37 ± 0.05 0.46 ± 0.12 0.22 ± 0.03 0.16 ± 0.03 0.15 ± 0.03 0.81 ± 0.07
Tumor 1.87 ± 0.05 2.64 ± 0.14 1.35 ± 0.06 1.46 ± 0.12 1.15 ± 0.07 0.68 ± 0.10
Skin 0.92 ± 0.05 0.55 ± 0.11 0.56 ± 0.34 0.38 ± 0.09 0.47 ± 0.01 0.31 ± 0.07
Bone 0.56 ± 0.32 0.58 ± 0.14 0.33 ± 0.05 0.33 ± 0.01 0.37 ± 0.08 0.42 ± 0.21
Heart 0.52 ± 0.15 0.31 ± 0.07 0.25 ± 0.02 0.25 ± 0.04 0.23 ± 0.03 0.14 ± 0.05
Lung 1.31 ± 0.35 0.78 ± 0.09 0.51 ± 0.08 0.55 ± 0.05 0.46 ± 0.05 0.48 ± 0.12
Liver 0.83 ± 0.17 0.94 ± 0.20 0.77 ± 0.09 1.01 ± 0.09 0.88 ± 0.01 0.36 ± 0.04
Kidney 3.50 ± 0.54 1.92 ± 0.26 1.63 ± 0.04 1.61 ± 0.17 1.15 ± 0.11 1.33 ± 0.12
Spleen 1.01 ± 0.48 1.23 ± 0.18 0.94 ± 0.06 1.30 ± 0.21 1.15 ± 0.10 0.28 ± 0.04
Pancreas 0.43 ± 0.25 0.29 ± 0.01 0.16 ± 0.01 0.18 ± 0.01 0.18 ± 0.03 0.15 ± 0.12
Stomach 1.25 ± 0.06 1.16 ± 0.22 0.87 ± 0.03 0.90 ± 0.13 0.66 ± 0.11 0.23 ± 0.04
Small intestine 1.30 ± 0.09 0.90 ± 0.35 0.83 ± 0.08 1.02 ± 0.14 0.73 ± 0.05 0.29 ± 0.14
Tumor/blood 3.58 ± 1.43 15.3 ± 1.06 27.9 ± 6.37 36.9 ± 13.1 28.7 ± 3.71 4.64 ± 2.19
Tumor/muscle 5.07 ± 0.69 6.07 ± 1.68 6.17 ± 1.02 8.99 ± 1.59 7.60 ± 0.94 0.83 ± 0.05
Tumor/lung 1.51 ± 0.48 3.41 ± 0.29 2.68 ± 0.51 2.65 ± 0.22 2.45 ± 0.14 1.44 ± 0.33
The data were reported as percent injected dose per gram ± standard deviation at different time points postinjection of 20 mCi radioactivity. A 1-hour blocking
experiment was performed with coinjection of 10 mg/kg c(RGDyK) (n = 3).
Figure 5. The 2D projection microPET images of SCID-bg mouse bearing
both subcutaneous and orthotopic NCI-H1975 tumors. The same mouse was
anesthetized and scanned with [18F]FDG (day 1) and 64Cu-DOTA-PEG-
E[cRGDyK)]2 (day 2). Left: Fifteen-minute static scan beginning 30 minutes
after intravenous injection of 200 Ci of FDG. Right: Fifteen-minute static
scan beginning 2 hours after injection of 300 Ci of 64Cu-DOTA-PEG-
E[cRGDyK)]2. (1) Primary orthotopic tumor in the upper lobe of the left lung;
(2) contralateral lung metastasis; (3) subcutaneous tumor; (4) heart; (5) liver;
(6) kidneys; and (7) bladder. Regions identified as tumors were confirmed by
cryosectioning and autoradiography following the 64Cu scan (Figure 6).
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peptide c(RGDyK) and evaluated the resulting 64Cu-DOTA-
c(RGDyK) radiotracer in the MDA-MB-435 breast cancer
xenograft model. Although the monomeric RGD peptide
tracer was able to delineate the tumor from background, it
also had high activity accumulation in liver. Similar to the 18F-
labeled dimeric RGD peptide, the DOTA-conjugated dimeric
RGD peptide tracer 64Cu-DOTA-E[c(RGDyK)]2 had almost
twice as much tumor uptake and somewhat increased renal
uptake compared with the corresponding monomeric RGD
peptide tracer 64Cu-DOTA-c(RGDyK). There is no significant
difference in blood clearance or liver activity accumulation
between the monomeric and dimeric forms. Encouraged by
the fact that PEGylation improved tumor targeting efficacy
and reduced biliary excretion of the 18F-labeled mono-
meric RGD peptide [22], we expected that the PEGylated
dimeric RGD peptide when labeled with 64Cu would also
have improved in vivo kinetics. Indeed, 64Cu-DOTA-PEG-
E[c(RGDyK)]2 had similar blood clearance, more rapid renal
clearance, and significantly reduced hepatic uptake com-
pared with 64Cu-DOTA-E[c(RGDyK)]2 [27]. However, tumor
uptake was also lowered due to the fact that the PEGylated
RGD dimer has lower receptor binding affinity than the
dimeric RGD peptide (Figure 3). We only tested one bifunc-
tional PEG (MW = 3400) in this study. We anticipate a
systematic investigation of the effect of PEG size and
geometry on tumor targeting and biodistribution of the radio-
label in an attempt to develop a radiotracer with high receptor
avidity and optimal systemic behavior.
Rapid tumor localization with relatively low normal
tissue uptake outside the gut makes 64Cu-DOTA-PEG-
E[c(RGDyK)]2 a promising agent for tumor imaging. The
proof-of-principle study presented here illustrates the
feasibility of NSCLC tumor and metastasis delineation with
this radiotracer. It is also striking that the PEGylated dimeric
RGD peptide tracer accumulated more specifically than FDG
in both primary and metastatic lung tumor lesions. However,
the significance of these findings is tempered by the fact that
the magnitude of tumor uptake may be too low (less than
3% ID/g) for peptide receptor radiotherapy (PRRT) applica-
tions. Further modifications may lead to identification of
radiolabeled integrin receptor ligands for both PET imaging
and targeted therapy.
Conclusion
The 64Cu-labeled PEGylated dimeric RGD peptide radio-
tracer was evaluated as an imaging agent for a human
NSCLC in which the avb3 integrin is strongly expressed. On
lung cancer cells (NCI-H1975) that express avb3 integrin,
binding of [125I]echistatin was inhibited by the ligand DOTA-
PEG-E[c(RGDyK)2 in a log dose–dependent manner, dem-
onstrating that the ligand is bound to cell surface receptors.
IC50 value of the PEGylated RGD dimer was lower than the
unmodified dimeric RGD peptide, suggesting a weakening of
ligand–receptor interaction on PEG modification. The distri-
bution of 64Cu-DOTA-PEG-E[c(RGDyK)]2 in a subcutane-
ously implanted NCI-H1975 xenograft model showed rapid
blood clearance and receptor-specific tumor activity accu-
mulation. Due to limited nonspecific uptake in normal organs
and tissues that do not express integrin avb3, excellent
tumor-to-background ratios were obtained at all time points
examined. MicroPET and whole-body digital autoradio-
graphic imaging of an orthotopic lung cancer model provided
clear delineation of a primary adenocarcinoma nodule as
Figure 6. Left: A coronal image of the same tumor-bearing mouse as shown in Figure 5. Both primary tumors as well as metastases are clearly identified. Right:
WBDA of a 50-m thick section correlating well with the coronal microPET slice shown on the left. (A) Primary orthotopic tumor in the upper lobe of the left lung; (B)
local metastasis of the primary tumor; (C) contralateral lung metastasis; (D) metastasis in the diaphragm; (E) subcutaneous tumor; and (F) liver.
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well as its metastases to the mediastinum, contralateral lung,
and diaphragm. The tumor visualization with 64Cu-DOTA-
PEG-E[c(RGDyK)]2 was superior to that with the metabolic
tracer [18F]FDG, which did not identify the metastatic lesions
due to intense cardiac uptake. The in vivo data strongly
suggest that peptide ligands of this class are promising for
imaging integrin expression in lung cancer. Further modifi-
cations to increase the magnitude of tumor uptake for
integrin-targeted internal radiotherapy are needed.
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